- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07557628
Studie av hypothalamus mikroglierespons som en funksjon av måltidets lipidinnhold hos mennesker. En enkeltsenter prospektiv kohortstudie hos friske mannlige forsøkspersoner (GLIPID)
Studie av den hypothalamiske mikrogliale responsen som funksjon av måltidets lipidinnhold hos mennesker. En enkeltsenter prospektiv kohortstudie hos friske mannlige forsøkspersoner
Obesity and its complications represent a growing public health problem in our society. A better understanding of the biological mechanisms involved in regulating food intake-and, more broadly, energy metabolism-should lead to improved management of this condition.
Recent studies have shown that eating a single meal can rapidly trigger the activation of the immune system. This leads to a postprandial, systemic, and transient inflammatory response (Emerson SR, Adv Nutr 2017). It is found in both healthy and obese individuals. It has also been observed in rodents, enabling preclinical studies to better understand the phenomenon. This postprandial inflammation is characterized by the activation of macrophages in the gastrointestinal tract and by elevated levels of circulating pro-inflammatory markers. At the cellular level, nutrients activate an intracellular molecular sensor called the inflammasome, which is a multiprotein complex formed by the oligomerization of proteins including NLRP3 (Nod-like receptors pyrin domain-containing 3) and ASC (Apoptosis-associated Speck-like protein containing a CARD domain). This sensor activates caspase 1, an enzyme that converts pro-interleukin 1β (pro-IL-1β) into its mature and active form, IL-1β. This molecular mechanism converts the nutritional signal into an immune response.
Under physiological conditions, this acute response appears to have beneficial effects on the body. Indeed, it plays a positive role in blood glucose control by stimulating insulin secretion and glucose utilization (Dror, Nat Immunol 2017). However, in the context of chronic overeating and excessive consumption of saturated fats and simple sugars, this systemic inflammation becomes harmful, promoting adipocyte hypertrophy, insulin resistance, hepatic steatosis, and vascular damage (Hotamisligil, Nature 2017).
In mice, our team recently demonstrated the existence of a postprandial inflammatory response in the central nervous system (Cansell, Glia 2021). This response occurs specifically in the hypothalamus, a brain structure involved in regulating food intake and controlling energy metabolism. It is characterized by microglial reactivity visible as early as 3 hours after the start of the postprandial phase. This postprandial microglial activation occurs after the ingestion of a high-fat meal, whereas it is rarely or never observed after the ingestion of a standard balanced meal. It is characterized by a morphological change in hypothalamic microglia, including an increase in the length of microglial processes and their branching. This gliosis is associated with increased expression of IL-1β in microglial cells. Thus, the postprandial gliosis observed 3 hours after a high-fat meal is inflammatory. Using a targeted genetic approach that allows for the ablation of the inflammasome in microglial cells, the team demonstrates that postprandial gliosis exerts a satiating effect, limiting subsequent food intake following a high-calorie, high-fat meal. Thus, microglial inflammation appears to be an additional component in the body's arsenal of adaptive homeostatic responses aimed at limiting energy intake.
Our clinical project will involve translating our basic findings in mice to humans. This will involve investigating postprandial hypothalamic gliosis in the human brain following a standard meal or a high-fat meal. The initial studies will be conducted exclusively in healthy male subjects to avoid the influence of the hormonal cycle on the hypothalamic response. The impact of physiological aging on the hypothalamic microglial inflammatory response will also be taken into account.
Studieoversikt
Status
Forhold
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Vincent SCHNEIDER
- Telefonnummer: +33 03 80 29 30 89
- E-post: vincent.schneider@chu-dijon.fr
Studiesteder
-
-
-
Dijon, Frankrike, 21000
- Rekruttering
- Chu Dijon Bourgogne
-
Ta kontakt med:
- Vincent SCHNEIDER
- Telefonnummer: +33 03 80 29 30 89
- E-post: vincent.schneider@chu-dijon.fr
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Healthy male volunteers
Beskrivelse
Inclusion Criteria:
- A person who has given oral consent
- Male
- Body Mass Index (BMI) between 18.5 and 30 kg/m²
- Age ≥ 20 years
Exclusion Criteria:
- A person subject to a measure of legal protection (guardianship, tutorship)
- A person subject to a judicial protective measure
- A person who is not enrolled in or eligible for a social security program
- Subject does not speak French
- Subjects with a pacemaker or any other contraindication to MRI
- Subjects with type 1 or type 2 diabetes
- Subjects with a chronic inflammatory condition
- Subjects with a neuropsychiatric condition
- Subjects taking anti-inflammatory medication or medication that affects the central nervous system
- Known hypersensitivity to foods provided during the study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Male subjects
Healthy volunteers to study the biological mechanisms that control food intake and energy metabolism |
Hormone and metabolic tests (insulin, IGF-1, leptin, blood glucose, ghrelin) Measurement of the T1 and T2 relaxation times in the hypothalamic region Eating habits and preferences Measurements of lean body mass, fat mass, body water and bone mass |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The difference in hypothalamic MRI signal intensity between the baseline state and the postprandial state observed after a balanced meal and after a high-fat meal for each subject.
Tidsramme: 2 days
|
Measurement of hypothalamic T2 relaxation time |
2 days
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Helsevesenets kvalitet, tilgang og evaluering
- Undersøkelsesteknikker
- Epidemiologiske metoder
- Prøvehåndtering
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Punkteringer
- Kirurgiske prosedyrer, operativ
- Farmakologiske handlinger
- Kjemiske handlinger og bruk
- Datainnsamling
- Helsevesenets evalueringsmekanismer
- Kvalitet på helsehjelpen
- Folkehelse
- Miljø og folkehelse
- Spesialbruk av kjemikalier
- Fordøyelsessystem Fysiologiske fenomener
- Fordøyelsessystem og orale fysiologiske fenomener
- Diagnostisk bruk av kjemikalier
- Undersøkelser og spørreskjemaer
- Blodprøveinnsamling
- Kontrastmedier
- Postprandial periode
Andre studie-ID-numre
- SCHNEIDER 2025
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .